Jiacheng Dai

Changsha, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Retraction: Randomized Trial of Relevance of Time-of-Day of Immunochemotherapy for Progression-free and Overall Survival in Patients With Non-small Cell Lung Cancer.

Retraction: Randomized Trial of Relevance of Time-of-Day of Immunochemotherapy for Progression-free and Overall Survival in Patients With Non-small Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 11, 2026

Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.

Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.

Journal: Nature medicine

Published: June 24, 2026

Exploring the relationship between potential hepatotoxicity and novel hormonal therapies in prostate cancer: a systematic review and meta-analysis.

Exploring the relationship between potential hepatotoxicity and novel hormonal therapies in prostate cancer: a systematic review and meta-analysis.

Journal: BMC cancer

Published: April 19, 2026

Comparative fall risk of patients treated with novel androgen receptor antagonists in prostate cancer: a systematic review and meta-analysis.

Comparative fall risk of patients treated with novel androgen receptor antagonists in prostate cancer: a systematic review and meta-analysis.

Journal: BMC cancer

Published: March 19, 2026

Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.

Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.

Journal: Cell reports. Medicine

Published: January 07, 2026

Circadian rhythms and lung cancer biology and immunotherapy: Emerging opportunities and challenges.

Circadian rhythms and lung cancer biology and immunotherapy: Emerging opportunities and challenges.

Journal: Chinese medical journal pulmonary and critical care medicine

Published: January 06, 2026

High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.

High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.

Journal: Cell reports. Medicine

Published: October 21, 2025

PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.

PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.

Journal: Nature communications

Published: September 13, 2025

Tumor immune microenvironment score predicts efficacy of immune checkpoint inhibitors-based regimens in advanced non-small cell lung cancer.

Tumor immune microenvironment score predicts efficacy of immune checkpoint inhibitors-based regimens in advanced non-small cell lung cancer.

Journal: Journal of translational medicine

Published: August 14, 2025

Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.

Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.

Journal: Nature medicine

Published: July 22, 2025

Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer.

Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer.

Journal: Cancer

Published: July 18, 2025

A translational study on the survival and molecular mechanism of PD-L1 expression in EGFR-mutant NSCLC treated with osimertinib.

A translational study on the survival and molecular mechanism of PD-L1 expression in EGFR-mutant NSCLC treated with osimertinib.

Journal: iScience

Published: June 11, 2025

Showing 1-12 of 19

Last Updated: 09/26/2026